About Us
About Us
  • Board Of Directors
  • Collaborators
  • Staff Directory
  • Job Openings
Our Legacy
Our Legacy
  • Achievements
  • History
  • Irene Diamond
  • Photo Gallery
Current Research
Current Research
  • Our Scientists and Labs
    • Paul Bieniasz
    • Cecilia Cheng-Mayer
    • Theodora Hatziioannou
    • David D. Ho
    • Yaoxing Huang
    • Martin Markowitz
    • Moriya Tsuji
  • Core Facilities
    • Personnel
    • Flow Cytometry
    • Microscope Imaging Facility
Clinical Trials
Clinical Trials
  • HIV+
    • Newly Infected With HIV
    • Living With HIV
    • Physicians
    • FAQ's
  • HIV.
    • Healthy Volunteer
    • FAQ's
Focus On HIV
Focus On HIV
  • Facts About HIV and AIDS
  • HIV Biology
    • The HIV Virus Particle
    • The HIV Replication Cycle
Giving Center
Giving Center
  • Online Giving
  • Other Giving Opportunities
  • Financial Summary
News Center
News Center
  • ADARC In The News
  • Seminars
  • Newsletters and Brochures
  • For Journalists
China Aids Initiative
China Aids Initiative
Multimedia Library
Multimedia Library
Talks at ADARC
Talks at ADARC
ADARC Gala
ADARC Gala
  • Gala video
  • Gala photo
  • leadership committee
  • Online Giving
Register for Updates
Register for Updates
Clinical Trails

Living with HIV


If You Are Living With HIV

If you are living with HIV, you may be eligible to participate in one of our clinical trials. Please click the links below if you would like more information about our open trials. If you are interested in participating, please contact Melissa La Mar at 212-327-7280 or e-mail her at mlamar@adarc.org.

Clinical Trials for Patients Living with HIV



(MMA-0591)
HIV Elite Controller Study
The focus of the studies to be conducted under this protocol and consent form is on the detailed analysis of host cellular and humoral immune responses, comprehensive human genome analysis and genomic analysis of the infecting viruses isolated from persons that control HIV Infection.
(MMA-0728)
A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy
The reason for doing this research is to find out if an investigational drug called GSK1349572 can help people with HIV. The purpose of this study is to test the safety of GSK1349572 and how well it works.

(MMA-0754)
Viral and Host factors in the transmission and pathogenesis of HIV
A Phase 2b Randomized, Double-Blind, Double-Dummy Trial of Once-Daily Doses of Cenicriviroc or Once-Daily EFV, Each with Open-Label FTC/TDF, in HIV-1-Infected, Antiretroviral Treatment-Naïve, Adult Patients

(MMA-0761)
A Phase 3b Randomized, Open-Label Study in Virologically-Suppressed, HIV-1 Infected Patients (GS-US 236-0121)
The purpose of this study is to see if HIV-infected subjects currently taking an antiretroviral (ARV) regimen consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) plus FTC/TDF (Truvada®) can safely switch to EVG/COBI/FTC/TDF STR without increasing the amount of virus in their blood.

 

(MMA-0781)
A Phase IIb, dose ranging study of oral GSK1265744 in combination with nucleoside reverse transcriptase inhibitors
The purpose of this study is to test the safety of GSK1265744 and how well it works. Three different doses of GSK1265744 will be compared in order to choose the best dose. About 200 people in the United States will take part in this study.